Register Login

Neurocrine Biosciences Inc (NBIX)

Director Gano Kyle 🟡 adjusted position in 36.4K shares (2 derivative) of NEUROCRINE BIOSCIENCES INC (NBIX) at $132.71 ($7.5M) Transaction Date: Jan 16, 2026 | Filing ID: 000002

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 2:21 p.m.

    🔍 Gano Kyle (Director)

    Company: NEUROCRINE BIOSCIENCES INC (NBIX)

    Report Date: 2026-01-16

    Transaction Summary:

    • Total transactions: 6
    • Derivative instruments: 2
    • Holdings reported: 0
    • Total shares acquired: 36,400
    • Total shares sold: 72,800

    Detailed Transactions and Holdings:

    • Acquired 34,588 shares of Common Stock at $35.99 per share (Direct)
      Date: 2026-01-16 | Code: M | equity_swap_involved: 0 | shares_owned_after: 174,995.00 | transaction_form_type: 4
    • Sold 34,588 shares of Common Stock at $132.7044 per share (Direct)
      Date: 2026-01-16 | Code: S | equity_swap_involved: 0 | shares_owned_after: 140,407.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Acquired 1,812 shares of Common Stock at $35.99 per share (Direct)
      Date: 2026-01-16 | Code: M | equity_swap_involved: 0 | shares_owned_after: 142,219.00 | transaction_form_type: 4
    • Sold 1,812 shares of Common Stock at $132.7143 per share (Direct)
      Date: 2026-01-16 | Code: S | equity_swap_involved: 0 | shares_owned_after: 140,407.00 | transaction_form_type: 4 | Footnotes: F1, F3
    • Sold 34,588 shares of Non-Qualified Stock Option at $35.99 per share (Derivative)
      Date: 2026-01-16 | Code: M | Expires: 2026-02-05 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4
    • Sold 1,812 shares of Incentive Stock Option at $35.99 per share (Derivative)
      Date: 2026-01-16 | Code: M | Expires: 2026-02-05 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4

    Footnotes:

    • F1: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 20, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
    • F2: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $131.42 to $133.98. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range
    • F3: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $131.49 to $133.79. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range
    • F4: The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning on March 5, 2016. These options were due to expire on February 5, 2026.

Search

News categories